Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 69INDUSTRY 46NIH 8OTHER_GOV 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 196Neoplasms 104Colorectal Neoplasms 91Stomach Neoplasms 80Uterine Cervical Neoplasms 71Carcinoma, Non-Small-Cell Lung 67Carcinoma, Hepatocellular 54Prostatic Neoplasms 48Lung Neoplasms 48Rectal Neoplasms 46Esophageal Neoplasms 39Pancreatic Neoplasms 37Colonic Neoplasms 36Ovarian Neoplasms 35Recurrence 33Head and Neck Neoplasms 33Neoplasm Metastasis 28Motor Activity 28Multiple Myeloma 27Small Cell Lung Carcinoma 26Melanoma 25Polycystic Ovary Syndrome 24Lymphoma, Non-Hodgkin 24Lymphoma 24Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Pain 20Brain Neoplasms 20Nasopharyngeal Carcinoma 18Hematologic Neoplasms 17

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Urogenital Neoplasms × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡